C-C Chemokine Receptor 3 Antagonism by the β-Chemokine Macrophage Inflammatory Protein 4, a Property Strongly Enhanced by an Amino-Terminal Alanine-Methionine Swap1

Allergic reactions are characterized by the infiltration of tissues by activated eosinophils, Th2 lymphocytes, and basophils. The β-chemokine receptor CCR3, which recognizes the ligands eotaxin, eotaxin-2, monocyte chemotactic protein (MCP) 3, MCP4, and RANTES, plays a central role in this process, and antagonists to this receptor could have potential therapeutic use in the treatment of allergy. We describe here a potent and specific CCR3 antagonist, called Met-chemokine β 7 (Ckβ7), that prevents signaling through this receptor and, at concentrations as low as 1 nM, can block eosinophil chemotaxis induced by the most potent CCR3 ligands. Met-Ckβ7 is a more potent CCR3 antagonist than Met- and aminooxypentane (AOP)-RANTES and, unlike these proteins, exhibits no partial agonist activity and is highly specific for CCR3. Thus, this antagonist may be of use in ameliorating leukocyte infiltration associated with allergic inflammation. Met-Ckβ7 is a modified form of the β-chemokine macrophage inflammatory protein (MIP) 4 (alternatively called pulmonary and activation-regulated chemokine (PARC), alternative macrophage activation-associated C-C chemokine (AMAC) 1, or dendritic cell-derived C-C chemokine (DCCK) 1). Surprisingly, the unmodified MIP4 protein, which is known to act as a T cell chemoattractant, also exhibits this CCR3 antagonistic activity, although to a lesser extent than Met-Ckβ7, but to a level that may be of physiological relevance. MIP4 may therefore use chemokine receptor agonism and antagonism to control leukocyte movement in vivo. The enhanced activity of Met-Ckβ7 is due to the alteration of the extreme N-terminal residue from an alanine to a methionine.

[1]  B. Walker,et al.  Enhanced Inhibition of Human Immunodeficiency Virus Type 1 by Met-Stromal-Derived Factor 1β Correlates with Down-Modulation of CXCR4 , 1999, Journal of Virology.

[2]  M. Rothenberg,et al.  CC Chemokine Receptor-3 Undergoes Prolonged Ligand-induced Internalization* , 1999, The Journal of Biological Chemistry.

[3]  S. Narula,et al.  Cutting edge: species specificity of the CC chemokine 6Ckine signaling through the CXC chemokine receptor CXCR3: human 6Ckine is not a ligand for the human or mouse CXCR3 receptors. , 1999, Journal of immunology.

[4]  W. Streit,et al.  Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Demartino,et al.  Binding and Functional Properties of Recombinant and Endogenous CXCR3 Chemokine Receptors* , 1998, The Journal of Biological Chemistry.

[6]  M. Rocchi,et al.  The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. , 1998, Journal of immunology.

[7]  N. Copeland,et al.  The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C. Martínez-A,et al.  The Coordinated Action of CC Chemokines in the Lung Orchestrates Allergic Inflammation and Airway Hyperresponsiveness , 1998, The Journal of experimental medicine.

[9]  O. Yoshie,et al.  Identification of Single C Motif-1/Lymphotactin Receptor XCR1* , 1998, The Journal of Biological Chemistry.

[10]  Masahiko Kuroda,et al.  Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.

[11]  Kouji Matsushima,et al.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.

[12]  D. Friend,et al.  Eotaxin is required for the baseline level of tissue eosinophils. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Cairns Js,et al.  Chemokines and HIV-1 second receptors: The therapeutic connection , 1998 .

[14]  C. Mackay,et al.  The C-C chemokine receptor CCR3 participates in stimulation of eosinophil arrest on inflammatory endothelium in shear flow. , 1998, The Journal of clinical investigation.

[15]  M. Mack,et al.  Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.

[16]  P. Verhaert,et al.  Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. , 1998, Journal of immunology.

[17]  M. Baggiolini Chemokines and leukocyte traffic , 1998, Nature.

[18]  Ji Ming Wang,et al.  Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor , 1998, European journal of immunology.

[19]  Dominique Schols,et al.  Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV , 1998, The Journal of Biological Chemistry.

[20]  C. Mackay,et al.  Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 Lymphocytes , 1998, The Journal of experimental medicine.

[21]  A. Mantovani,et al.  Identification of the CC chemokines TARC and macrophage inflammatory protein‐1β as novel functional ligands for the CCR8 receptor , 1998, European journal of immunology.

[22]  S. Goerdt,et al.  Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. , 1998, Journal of immunology.

[23]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[24]  R. Nibbs,et al.  Cloning and Characterization of a Novel Promiscuous Human β-Chemokine Receptor D6* , 1997, The Journal of Biological Chemistry.

[25]  T. Schall,et al.  Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.

[26]  A. Proudfoot,et al.  The CC chemokine antagonist Met‐RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3 , 1997, European journal of immunology.

[27]  C. Mackay,et al.  Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils , 1997, Current Biology.

[28]  S. Kunkel,et al.  Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. , 1997, The Journal of clinical investigation.

[29]  C. Mackay,et al.  Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. , 1997, Science.

[30]  C. Mackay,et al.  High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. , 1997, The Journal of clinical investigation.

[31]  Y. Sakaki,et al.  A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. , 1997, Journal of immunology.

[32]  P. Clapham HIV and chemokines: ligands sharing cell-surface receptors. , 1997, Trends in cell biology.

[33]  M. Baggiolini,et al.  Eotaxin-2, a Novel CC Chemokine that Is Selective for the Chemokine Receptor CCR3, and Acts Like Eotaxin on Human Eosinophil and Basophil Leukocytes , 1997, The Journal of experimental medicine.

[34]  T. Mcclanahan,et al.  A dendritic-cell-derived C–C chemokine that preferentially attracts naive T cells , 1997, Nature.

[35]  M. Peitsch,et al.  The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and Expressed Sequence Tag Databases , 1997, Journal of leukocyte biology.

[36]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[37]  P. Leder,et al.  Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia , 1997, The Journal of experimental medicine.

[38]  Q. Hamid,et al.  Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. , 1996, Journal of immunology.

[39]  B. Premack,et al.  Chemokine receptors: Gateways to inflammation and infection , 1996, Nature Medicine.

[40]  S. Nishikawa,et al.  Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 , 1996, Nature.

[41]  P. Murphy Chemokine receptors: structure, function and role in microbial pathogenesis. , 1996, Cytokine & growth factor reviews.

[42]  C. Mackay,et al.  Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils , 1996, The Journal of experimental medicine.

[43]  B. Dewald,et al.  RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors (*) , 1996, The Journal of Biological Chemistry.

[44]  J. Demartino,et al.  Cloning, expression, and characterization of the human eosinophil eotaxin receptor , 1996, The Journal of experimental medicine.

[45]  B. Dewald,et al.  Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin , 1996, The Journal of experimental medicine.

[46]  M. Montjovent,et al.  Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist (*) , 1996, The Journal of Biological Chemistry.

[47]  M. Baggiolini,et al.  Deletion of the NH2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil chemoattractant , 1996, The Journal of experimental medicine.

[48]  M. Teixeira,et al.  Mechanisms and pharmacological manipulation of eosinophil accumulation in vivo. , 1995, Trends in pharmacological sciences.

[49]  T. Springer Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.

[50]  K. Blaser,et al.  An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. , 1991, Journal of immunological methods.

[51]  E. Wright,et al.  Identification and characterization of an inhibitor of haemopoietic stem cell proliferation , 1990, Nature.

[52]  J. Cairns,et al.  Chemokines and HIV-1 second receptors: The therapeutic connection , 1998, Nature Medicine.

[53]  D. Loegering,et al.  Immunobiology of eosinophils. , 1984, Annual review of immunology.